-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Initiates Coverage On Kazia Therapeutics with Buy Rating, Announces Price Target of $35

Benzinga·10/21/2026 13:09:23
Listen to the news
Guggenheim analyst Paul Jeng initiates coverage on Kazia Therapeutics (NASDAQ:KZIA) with a Buy rating and announces Price Target of $35.